Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Catalent Pharma Solutions history
Catalent Pharma Solutions company history timeline
In 2007, the pharmaceutical technologies and services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions.
In 2012, Catalent acquired Aptuit, a clinical supply company.
In 2013, Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co, a China-based company, and Relthy Laboratories in Brazil.
The shares began trading on the NYSE on 31 July 2014, under the ticker symbol CTLT.
Catalent announced its initial public offering in July 2014.
In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies.
In 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with oncology development, and bought Pharmatek Laboratories to add spray drying to their manufacturing capabilities.
In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, allowing Catalent to expand their biologic manufacturing.
In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133 million deal.
In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra.
In June 2019, Catalent acquired Bristol-Myers' European launch pad to expand its global CDMO.
Later in 2019, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method.
Alessandro Maselli was appointed as president and chief operating officer in 2019, a newly created position within Catalent.
In January 2020, Catalent purchased a manufacturing facility located in Anagni, Italy, from Bristol-Myers Squibb, to manufacture and package biologic and oral solid dose products for multiple companies.
In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million.
In 2020, Catalent partnered with multiple drugmakers, including Pfizer, Johnson & Johnson, AstraZeneca, and Moderna to provide manufacturing, vial filling and packaging capabilities for COVID-19 vaccine candidates.
In August 2021, Catalent announced plans to acquire nutritional supplement company Bettera Holdings LLC for $1 billion.
In October 2021, Catalent opened a 6,000 square-meter clinical supply facility in Shiga, Japan.
Rate Catalent Pharma Solutions' efforts to communicate its history to employees.
Catalent Pharma Solutions jobs
Do you work at Catalent Pharma Solutions?
Does Catalent Pharma Solutions communicate its history to new hires?
Catalent Pharma Solutions competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Charles River Labs | 1947 | $4.0B | 18,400 | 351 |
| Parexel International | 1983 | $2.4B | 18,900 | 1,336 |
| Juniper Pharmaceuticals | 1986 | $48.8M | 115 | - |
| West-Ward Pharmaceuticals | 1946 | $150.0M | 249 | 57 |
| DPT Laboratories | 1938 | $320.0M | 510 | - |
| Akorn | 1971 | $682.4M | 2,227 | - |
| DSM Pharmaceuticals Inc | 1993 | $850.0M | 1,200 | - |
| ALZA Corporation | 1968 | $200.0M | 10,000 | - |
| Paddock Laboratories | 1977 | $100.5M | 51 | - |
| Actavis Laboratories FL, Inc. | 2002 | $162.9M | 900 | - |
Catalent Pharma Solutions history FAQs
Zippia gives an in-depth look into the details of Catalent Pharma Solutions, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Catalent Pharma Solutions. The employee data is based on information from people who have self-reported their past or current employments at Catalent Pharma Solutions. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Catalent Pharma Solutions. The data presented on this page does not represent the view of Catalent Pharma Solutions and its employees or that of Zippia.
Catalent Pharma Solutions may also be known as or be related to Catalent, Catalent Inc, Catalent Pharma Solutions and Catalent, Inc.